Trial Profile

An Open-Label, Multi-Center, Phase 2 Clinical Study to Evaluate Efficacy, Safety, and Tolerability of KN046 in Combination With Axitinib in Subjects With Advanced Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Erfonrilimab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

29 Apr 2024 Planned End Date changed from 26 Mar 2024 to 26 Dec 2027.
29 Apr 2024 Planned primary completion date changed from 29 Mar 2023 to 29 May 2027.
24 Oct 2023 Preliminary Results(As of data cut-off date (Mar 17, 2023),n= 22 ) presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com